Sagimet Biosciences (SGMT) Competitors $8.73 -0.32 (-3.54%) Closing price 04:00 PM EasternExtended Trading$8.88 +0.15 (+1.67%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMT vs. GPCR, AMPH, VERV, SYRE, AKBA, RCUS, COLL, AVXL, IMNM, and ELVNShould you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Verve Therapeutics (VERV), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), Arcus Biosciences (RCUS), Collegium Pharmaceutical (COLL), Anavex Life Sciences (AVXL), Immunome (IMNM), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry. Sagimet Biosciences vs. Its Competitors Structure Therapeutics Amphastar Pharmaceuticals Verve Therapeutics Spyre Therapeutics Akebia Therapeutics Arcus Biosciences Collegium Pharmaceutical Anavex Life Sciences Immunome Enliven Therapeutics Sagimet Biosciences (NASDAQ:SGMT) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings. Do insiders and institutionals have more ownership in SGMT or GPCR? 87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by insiders. Comparatively, 9.4% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, SGMT or GPCR? Sagimet Biosciences has a beta of 3.37, meaning that its stock price is 237% more volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.89, meaning that its stock price is 289% less volatile than the S&P 500. Do analysts recommend SGMT or GPCR? Sagimet Biosciences currently has a consensus target price of $26.33, suggesting a potential upside of 201.64%. Structure Therapeutics has a consensus target price of $75.71, suggesting a potential upside of 364.22%. Given Structure Therapeutics' higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Sagimet Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to SGMT or GPCR? In the previous week, Structure Therapeutics had 9 more articles in the media than Sagimet Biosciences. MarketBeat recorded 14 mentions for Structure Therapeutics and 5 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.72 beat Structure Therapeutics' score of -0.10 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is SGMT or GPCR more profitable? Structure Therapeutics' return on equity of -20.76% beat Sagimet Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -35.21% -34.09% Structure Therapeutics N/A -20.76%-19.86% Which has preferable valuation & earnings, SGMT or GPCR? Sagimet Biosciences has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M133.87-$45.57M-$1.76-4.96Structure TherapeuticsN/AN/A-$122.53M-$1.05-15.53 SummaryStructure Therapeutics beats Sagimet Biosciences on 7 of the 12 factors compared between the two stocks. Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMT vs. The Competition Export to ExcelMetricSagimet BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$277.61M$2.97B$5.44B$9.61BDividend YieldN/A2.46%4.61%4.14%P/E Ratio-4.967.0321.9724.23Price / Sales133.87314.42449.4898.71Price / CashN/A41.8536.4258.36Price / Book1.727.318.185.64Net Income-$45.57M-$54.43M$3.26B$265.68M7 Day Performance5.82%-0.01%1.15%2.51%1 Month Performance-4.59%5.13%2.82%1.88%1 Year Performance220.96%10.24%28.41%24.00% Sagimet Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMTSagimet Biosciences3.1269 of 5 stars$8.73-3.5%$26.33+201.6%+244.1%$277.61M$2M-4.968Upcoming EarningsAnalyst UpgradeGPCRStructure Therapeutics1.8627 of 5 stars$16.78-4.6%$76.17+353.9%-52.4%$1.01BN/A-19.29136News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionAMPHAmphastar Pharmaceuticals4.3113 of 5 stars$21.40+0.9%$32.33+51.1%-44.4%$999.82M$731.97M7.752,028Trending NewsAnalyst ForecastVERVVerve Therapeutics3.3775 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110Upcoming EarningsSYRESpyre Therapeutics2.6381 of 5 stars$16.16-0.6%$53.40+230.4%-37.9%$980.08M$890K-4.2973News CoveragePositive NewsEarnings ReportAnalyst ForecastGap DownAKBAAkebia Therapeutics3.9457 of 5 stars$3.76+1.1%$6.75+79.5%+171.2%$977.01M$160.18M-17.90430News CoverageRCUSArcus Biosciences2.2596 of 5 stars$9.22+0.6%$21.29+131.0%-33.4%$969.91M$258M-2.20500Earnings ReportAnalyst ForecastAnalyst RevisionCOLLCollegium Pharmaceutical3.9118 of 5 stars$31.09+3.4%$43.75+40.7%-4.9%$966.20M$631.45M25.48210Trending NewsAVXLAnavex Life Sciences3.6797 of 5 stars$10.82-3.4%$44.00+306.7%+84.5%$956.67MN/A-19.6740IMNMImmunome1.698 of 5 stars$10.95+3.4%$23.33+113.1%-20.8%$921.46M$9.04M-3.4440News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastELVNEnliven Therapeutics2.7149 of 5 stars$18.74+0.1%$41.20+119.9%-17.4%$919.07MN/A-9.7650Upcoming Earnings Related Companies and Tools Related Companies Structure Therapeutics Competitors Amphastar Pharmaceuticals Competitors Verve Therapeutics Competitors Spyre Therapeutics Competitors Akebia Therapeutics Competitors Arcus Biosciences Competitors Collegium Pharmaceutical Competitors Anavex Life Sciences Competitors Immunome Competitors Enliven Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGMT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
